Genentech Provides Update on Nutropin AQ® (somatropin) NuSpin® formulations in the United States

On December 31, 2024, Genentech will discontinue all Nutropin AQ® (somatropin) NuSpin® formulations in the United States.

The decision to discontinue Nutropin was made after a thorough assessment by Genentech and is based on a combination of business considerations and the availability of alternative growth hormone options for patients. This action is unrelated to the current supply shortage or any product quality, safety, or efficacy issues. The U.S. Food and Drug Administration (FDA) has been notified.

Ensuring the well-being of patients is Genentech’s top priority, and we are committed to supporting patients and healthcare providers during this transition. Alternative growth hormone options are commercially available; we encourage patients to discuss treatment options with their doctor. Any questions from those impacted by this transition can call the Nutropin support line at 1-866-Nutropin (866-688-7674) or click here.

About Genentech

Founded more than 40 years ago, Genentech is a leading biotechnology company that discovers, develops, manufactures and commercializes medicines to treat patients with serious and life-threatening medical conditions. The company, a member of the Roche Group, has headquarters in South San Francisco, California. For additional information about the company, please visit